insights_auto
Why is NOVOBN up 5,67%?
Dive Deeperchevron_right
NOVOBN:BMV
Novo Nordisk A/S
764,50 MXN
arrow_upward
+5,67%(+41,00) 1D
16-окт., 14:00:00 GMT-6 · MXN
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NOVOBN...
Open
728,00 MXN
High
764,50 MXN
Low
728,00 MXN
Mkt. cap
132,00 млд
Avg. vol.
386,00
Volume
21,00
52-wk high
1 149,99 MXN
52-wk low
630,00 MXN
No. of employees
67 миң
Open
728,00 MXN
High
764,50 MXN
Low
728,00 MXN
Mkt. cap
132,00 млд
Avg. vol.
386,00
Volume
21,00
52-wk high
1 149,99 MXN
52-wk low
630,00 MXN
No. of employees
67 миң
News stories
From web sources and news partners
Simply Wall Street
·
1 саат мурун
Novo Nordisk (NVO) Stock May Be Undervalued As Buybacks Continue
The Motley Fool
·
1 күн мурун
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Yahoo Finance
·
1 күн мурун
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
TradingKey
·
2 күн мурун
Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66,7 миң
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, Дания
SectorPharmaceutical industry
Websitenovonordisk.com